Hee-Jin Im

Prof. Dr. Hee-Jin Im

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Epilepsy & Behavior
Verified
Journal Article
Closed access
HIHee-Jin Im
Hee-Jin Im
SPSeong-Ho Park
Seong-Ho Park
SBShin-Hye Baek
Shin-Hye Baek
MCMin Kyung Chu
Min Kyung Chu
KYKwang Ik Yang
Kwang Ik Yang
CYChang-Ho Yun
Chang-Ho Yun

5 December 2023 in Neurology
Verified
Journal Article
Open access
PDF file
WLWoo-Jin Lee
Woo-Jin Lee
SBShin-Hye Baek
Shin-Hye Baek
HIHee-Jin Im
Hee-Jin Im
SLSeung Ku Lee
Seung Ku Lee
JYJee-Eun Yoon
Jee-Eun Yoon
CYChang-Ho Yun
Chang-Ho Yun
Background and Objectives To evaluate the prevalence of REM sleep behavior disorder (RBD) and its possible prodromal conditions, isolated dream enactment behavior (DEB) and isolated REM without atonia (RWA), in a general population sample, and the factors associated with diagnosis and symptom frequency. Methods From a population-based prospective cohort in Korea, 1,075 participants (age 60.1 ± 7.0 years; range 50–80 years; men 53.7%) completed the RBD screening questionnaire (RBDSQ), a structured telephone interview for the presence and characteristics of repeated DEB, and home polysomnography (PSG). RWA was measured on submentalis EMG, including 30-second epoch-based tonic and phasic activity as well as 3-second mini-epoch–based phasic and any EMG activities. Based on the presence of repeated DEB and any EMG activity of ≥22.3%, we categorized the participants into no RBD, isolated RWA, isolated DEB, and RBD groups. Results RBD was diagnosed in 20 participants, isolated RWA in 133 participants, and isolated DEB in 48 participants. Sex and DEB frequency-adjusted prevalence of RBD was 1.4% (95% CI 1.0%–1.8%), isolated RWA was 12.5% (95% CI 11.3%–13.6%), and isolated DEB was 3.4% (95% CI 2.7%–4.1%). Total RBDSQ score was higher in the RBD and isolated DEB groups than in the isolated RWA and no RBD group (median 5 [interquartile range (IQR) 4–6] for RBD, median 4 [IQR 3–6] for isolated DEB, median 2 [IQR 1–3] for isolated RWA, and median 2 [IQR 1–4] for no RBD groups, p < 0.001). RBDSQ score of ≥5 had good specificity but poor positive predictive value (PPV) for RBD (specificity 84.1% and PPV 7.7%) and its prodromal conditions (specificity 85.2% and PPV 29.1%). Among the RWA parameters, any EMG activity showed the best association with the RBD and its possible prodromes (area under the curve, 0.917). Three-second mini-epoch–based EMG activity and phasic EMG activity were correlated with the frequency of DEB (standardized Jonckheere-Terpstra statistic [std. J-T static] for trend = 0.488, p < 0.001, and std. J-T static = 3.265, p = 0.001, respectively). Discussion This study provides prevalence estimates of RBD and its possible prodromal conditions based on a structured telephone interview and RWA measurement on PSG from the general population.

20 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HIHee-Jin Im
Hee-Jin Im
JKJee Hyun Kim
Jee Hyun Kim
CYChang-Ho Yun
Chang-Ho Yun
DKDong Wook Kim
Dong Wook Kim
JOJeeyoung Oh
Jeeyoung Oh
Background: Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron–dopamine dysregulation and immune system alteration. We aimed to assess the effects of serum hepcidin, an iron-regulating hormone, in drug-naive RLS patients compared to healthy controls and to evaluate its role in helping to predict clinical improvement after treatment with dopamine agonist. Methods: Nonanemic and drug-naive RLS patients (n = 18) and healthy controls (n = 15) were enrolled. The serum hepcidin and iron-related values in the serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 patients. Information about sociodemographic characteristics, sleep-related profiles, mood and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results: Serum hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/mL, p = 0.357). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression and anxiety. Conclusions: This study demonstrates the role of hepcidin in evaluating the positive therapeutic response in RLS.

28 August 2019 in Chronobiology International
Verified
Journal Article
Closed access
HIHee-Jin Im
Hee-Jin Im
SBSeol-Hee Baek
Seol-Hee Baek
CYChang-Ho Yun
Chang-Ho Yun
MCMin Kyung Chu
Min Kyung Chu
Migraine attacks have a time preference of headache attack (TPHA). Chronotype is the propensity for an individual to sleep at a particular time during a 24-h period. However, limited evidence exists regarding the association between TPHA and chronotype in individuals with migraine or tension-type headache (TTH). The aim of the present study is to investigate TPHA and chronotype in individuals with migraine and TTH, which are two of the most common primary headaches. One hundred sixty-nine first-visit migraine and TTH participants were consecutively enrolled. Information on sleep onset time and wake up time on workdays and free days, and TPHA were investigated with a face-to-face interview using a questionnaire booklet. Chronotype was assessed, using the midpoint of sleep on free days, corrected for sleep extension on free days (MSFsc), by subtracting one-half of the average weekly sleep duration. Headache frequency per month, headache intensity, impact of headache, sleep quality, daytime sleepiness, insomnia severity, and mood status were also assessed. Time preference of headache attack was reported for 45.5% and 44.8% of participants with migraine and TTH, respectively. Migraineurs with TPHA had an earlier MSFsc than did migraineurs without TPHA (1:18 a.m. ± 282 min vs. 4:18 a.m. ± 186 min; p = .022). Among migraineurs with TPHA, a later MSFsc was associated with a later preferential time of attack (β = 1.3, 95% confidence interval [CI] = 0.6–2.1, p = .004). A later MSFsc was significantly correlated with a higher headache frequency per month among migraineurs with TPHA (β = 1.9, 95% CI = 0.3–3.4, p = .023), but was not significantly correlated among migraineurs without TPHA (β = 1.4, 95% CI −1.7–4.4, p = .332). Among TTH participants with TPHA, MSFsc was not significantly associated with a preferential time of attack (β = −0.2, 95% CI = −1.0 to 0.6, p = .611). Headache frequency was not associated with MSFsc among TTH participants with TPHA (β = 0.2, 95% CI = −1.2 to 1.6, p = .792) or among TTH participants without TPHA (β = 0.4, 95% CI = −0.5 to 1.3, p = .354). In conclusion, approximately one-half of participants with migraine and TTH reported having TPHA. Migraineurs with TPHA had an earlier chronotype than did migraineurs without TPHA. A later chronotype was associated with increased headache frequency and a later time of attack among migraineurs with TPHA. Among participants with TTH, TPHA and headache frequency were not significantly associated with chronotype.


26 April 2023 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
JYJee-Eun Yoon
Jee-Eun Yoon
DODana Oh
Dana Oh
IHInha Hwang
Inha Hwang
JPJung A Park
Jung A Park
HIHee-Jin Im
Hee-Jin Im
CYChang-Ho Yun
Chang-Ho Yun
Yoon JE, et al. J Clin Neurol. 2023 Apr;19:e36. https://doi.org/10.3988/jcn.2022.0268